Clinical Presentation, Risk Factors, and Outcomes of Cardiovascular Disease in a Military Cardiac Center in Yemen

Prepared for Submission to medRxiv

First Author & Corresponding:

Abdulelah Mansoor Mohammed Al-Ganad
MSc in Epidemiology and Medical Biostatistics
Al-Razi University, Sana'a, Yemen
Email: 4s4.alganad@gmail.com

Principal Supervisor:

Dr. Ahmed Al-Motarreb
Professor of Cardiology, Head of Medical Department
Faculty of Medicine – Sana'a University
Email: amotarreb2@su.edu.ye

Co-authors:

Dr. Taha Al-Maimoony
Associate Professor of Cardiology
Faculty of Medicine – Sana'a University

Email: Almaimoonytaha@gmail.com

Prof. Nabil Al-Rabeei
Professor of Epidemiology and Medical Biostatistics
Faculty of Medical Sciences – Al-Razi University
Email: N.alrabeei@su.edu.ye

Dr. Abdulaziz Mohammed Ali Aonallah
Consultant Cardiologist
Military Cardiac Center, Sana'a
Email: drazizaonccmh@gmail.com

Dr. Esmail Mohamed Sad Al-Dabis

Epidemiological Surveillance Program, Ministry of Public Health and Population – Yemen
Associate Professor of Public Health and Epidemiology
Email: ismailnbtrc13@gmail.com

1.0 Abstract

Background: Cardiovascular diseases (CVDs) are a growing public health concern in Yemen, yet detailed data from local facilities are limited. This study aimed to evaluate clinical characteristics, risk factors, and outcomes of CVDs in a military cardiac center.

Aim: To evaluate the clinical characteristics, risk factors, and outcomes of cardiovascular diseases (CVDs) among patients admitted to the Coronary Care Unit (CCU).

Setting: The study was conducted at the Military Cardiac Center in Sana'a, which includes a 7-bed CCU for cardiac cases, 75 general ward beds, 4 beds in the emergency department, and 2 beds in the operating theater.

Methods: A retrospective cohort study was conducted at the Military Cardiac Center in Sana'a, including all patients admitted to the Coronary Care Unit (CCU) in 2019. Clinical data were extracted from both electronic and archived paper records, including prior medical histories dating back to 2008 or 2010 when available. Variables included demographics, clinical presentations, diagnoses, prior cardiac history, and outcomes. Statistical analyses were performed using descriptive statistics, chi-square tests, ANOVA, and univariate logistic regression to identify predictors of in-hospital and 5-year mortality.

Results:

A total of 446 patients were included (mean age:53.0 plus/minus 13.6 years; 84% male). The most common diagnoses were acute coronary syndrome (ACS, 60.9%), acute decompensated heart failure (ADHF, 13%), valvular heart disease (VHD, 9%), and cardiogenic shock (5%). Risk factors included khat use (76%), smoking (61%), hypertension (41%), diabetes (31%), and dyslipidemia (4.9%). Younger patients had higher rates of smoking, khat use, and prior myocardial infarction or PCI, while older

patients had more diabetes, hypertension, and dyslipidemia. Significant predictors of in-hospital mortality included diabetes (OR=2.6), rheumatic heart disease (RHD, OR=2.4), cardiogenic shock (OR=11.3), heart failure (OR=9.2), sepsis (OR=31.1), and cardiac arrest (OR=74.0). For 5-year mortality, key predictors were unstable angina (OR=8.7), ACS (OR=4.0), elective PCI (OR=2.9), and khat use (OR=2.0).

Conclusion

CVDs in Yemen affect relatively young patients and are driven by modifiable, region-specific risk factors. Limited access to emergency interventions and late hospital presentation contribute to poor outcomes. Public awareness, preventive measures, and improved cardiac care infrastructure are urgently needed.

Recommendations: Enhancing public awareness, expanding access to cardiac emergency care, and strengthening preventive services are crucial to reducing mortality and improving outcomes. **Implementing these measures urgently can substantially mitigate the burden of cardiovascular disease in Yemen.**

Keywords: Cardiovascular disease, ACS, STEMI, risk factors, logistic regression, Yemen

2.0 Introduction

Cardiovascular diseases (CVDs)—including coronary artery disease, stroke, rheumatic heart disease, and peripheral arterial disease—remain the leading global cause of death. According to the World Health Organization, CVDs caused an estimated 17.9 million deaths in 2019, accounting for 32% of all global mortality **(1)**. Over 75% of these deaths occur in low- and middle-income countries (LMICs), where delayed diagnosis, limited access to specialized care, and prevalent behavioral risk factors—such as tobacco use, unhealthy diets, physical inactivity, and in Yemen, khat chewing—significantly contribute to the burden ***(1, 2)***.

Ischemic heart disease and stroke are responsible for nearly 87% of CVD-related deaths, many of which occur prematurely in individuals under age 70(3). In Yemen, CVDs account for over 33% of all deaths, making them the country's leading cause of mortality (**4**) This

crisis is exacerbated by ongoing conflict, economic hardship, weak infrastructure, and limited availability of evidence-based care. Modifiable risk factors—including khat use, malnutrition, and chronic stress—remain highly prevalent **(2).**

While high-income countries have reduced CVD mortality through early detection and advanced care, Yemen still lacks robust data, particularly on critically ill patients in coronary care units (CCUs). Addressing this knowledge gap is essential for improving prevention and outcomes.

Therefore, this study aims to characterize the epidemiological profile, clinical features, risk factors, and outcomes of CVD patients admitted to the CCU at the Military Cardiac Center in Sana'a. By generating local evidence, the findings can inform targeted interventions and strengthen cardiac care within Yemen's fragile healthcare system.

3.0 Objectives and Hypotheses of the Study

3.1 Study Objectives

3.1.1 General Objective

To describe the clinical presentation, risk factors, course, and outcomes of cardiovascular disease among patients admitted to the Military Cardiac Center in Sana'a, Yemen.

3.1.2 Specific Objectives

1. To determine the pattern of CVD among CCU-admitted patients.
2. To examine the distribution of CVD by demographic characteristics.
3. To identify major cardiovascular risk factors in the study population.
4. To assess hospital, stay duration, admission pathways, and treatment outcomes.
5. To compare the clinical presentation and outcomes of ACS between older and younger patients.
6. To identify predictors of in-hospital complications and mortality in high-risk cardiac patients.

4.0 Research Methodology

4.1 Study Setting The study was conducted at the Military Cardiac Center in Sana'a, Yemen, a national referral hospital established in 2008. It includes a 7-bed Coronary Care Unit (CCU) staffed by cardiologists and nurses, and provides diagnostic and interventional cardiac services.

4.2 Study Design > This retrospective cohort study included all patients admitted to the CCU in 2019. In addition to clinical data during admission, available past records—electronic or paper-based—were reviewed and entered when accessible. For most patients, prior medical histories were retrieved, in some cases dating back to 2008 or 2010. This enriched the dataset with baseline cardiovascular risk factors and comorbidities, strengthening the risk and outcome analyses.

4.3 Study Population All adult patients (≥18 years) admitted to the CCU at the Military Cardiac Center in Sana'a during 2019 were included using total population sampling.

4.4 Inclusion and Exclusion Criteria

- **Inclusion:** Adults (≥18 years) admitted to the CCU in 2019 with complete cardiac records.
- **Exclusion:** Patients <18 years, early deaths (<6 hours), non-cardiac admissions, and incomplete data

4.5 Sample Size and Sampling Method A total enumeration approach was used, including all eligible records from January to December 2019 identified via electronic and paper archives.

4.6 Data Collection Tools and Techniques Data were collected using a structured checklist adapted from previous studies ***(5, 6)***.Variables included demographics, risk factors (smoking, khat use, diabetes, hypertension, dyslipidemia), clinical characteristics (symptoms, diagnosis, complications), laboratory data (e.g., lipid profile, FBS, CK-MB), imaging and procedure data (echocardiography, CAG, PCI), treatment details, and outcomes (discharge, mortality).

4.7 A pilot test A pilot test on 10% of records assessed checklist clarity and consistency. Revisions were made accordingly before full data collection.

***4*.8 Validity and Reliability** Face and content validity were confirmed by experts in cardiology and epidemiology. The checklist, adapted from validated tools, showed good inter-rater reliability ($\kappa = 0.70$).

.4.9 Statistical Analysis Data were analyzed using SPSS (version 2024):

Data were analyzed using SPSS v.2024. Descriptive statistics, chi-square tests, and one-way ANOVA assessed distributions and group differences. Univariate logistic regression identified predictors of in-hospital and 5-year mortality, reporting ORs, CIs, and p-values

4.10 Study Variables Dependent variable:

The outcome variable was mortality (in-hospital and 5-year); predictors included sociodemographic, clinical, risk, and treatment variables.

4.11 Ethical Consideration. The study received ethical approval from Al-Razi University and access permission for patient records was obtained from the Military Cardiac Center management.

5.0 Result

5.1 Age Group Distribution

The mean age of patients admitted to the CCU was 53.6 ± 13.6 years. The age group of 18–30 years was represented as 7%, from 31-40 years 8%, from 41 – 50 years 26%, from 51-60 years 34%, from 61-70 years 16%, and 9% represents> 70 years.

5.2. Distribution of Cases by Final Diagnosis and Sex (Table 5.1)

that acute coronary syndrome (60.9%)—mainly STEMI (52%)—was the most common diagnosis, especially in males. Heart failure (13%) and rheumatic valvular disease (9%) were more common in females ($p < 0.001$ and $p = 0.036$). Less frequent conditions included cardiomyopathy (4%), cardiogenic shock (5%), and others (2.2%). The data emphasize the high burden of ischemic heart

disease in males and structural heart disease in females, highlighting the need for gender-sensitive care in Yemen

Table 5.1: Distribution of cases by final diagnosis of the admission event and Sex.

Final diagnosis of the admission event	Male no (%)	Female no (%)	Total	P.value
1. ACS	241 (64%)	31 (44%)	272 (60.9%)	**0.002**
2. ACS STEMI	131 (35%)	12 (17%)	143 (52.3)	**0.002**
3. ACS NSTEMI	52 (14%)	8 (11%)	60 (22)	0.374
4. ACS SA	5 (1%)	0 (0%)	5 (1.8%)	0.424
5. ACS UA	53 (14%)	11 (16%)	64 (23.5%)	0.421
6. ADHF	47 (13%)	10 (14%)	57 (13%)	0.402
7. Arrhythmia	4 (1%)	1 (1%)	5 (1%)	0.576
8. Cardiogenic Shock	21 (6%)	2 (3%)	23 (5%)	0.270
9. Congenital Heart Disease	11 (3%)	6 (9%)	17 (4%)	**0.036**
10. COPD	3 (1%)	1 (1%)	4 (1%)	0.496
11. DCMP	17 (5%)	1 (1%)	18 (4%)	0.195
12. Hypertensive Emergency	1(0%)	1(1%)	2(0%)	0.290
13. LV THROMBUS	2 (1%)	0 (0%)	2 (0%)	0.710
14. P.Embolism	2 (0%)	0 (0%)	2 (0%)	0.710
15. P.HTN	1 (0%)	1 (1%)	2 (0%)	0.290
16. Pericarditis	2 (1%)	0 (0%)	2 (0%)	0.710
17. VHD	24 (6%)	16 (23%)	40 (9%)	**0.000**
TOTAL	**376 (100%)**	**70 (100%)**	**446 (100%)**	

5.3. Frequency of CVD risk factors among cases (Table 5.2)

As shown in Table 5.2, khat chewing (76%) and smoking (61%) were the most frequent risk factors, followed by hypertension (41%) and diabetes (31%). About 40% had three or more risk factors. Men reported more khat, smoking, and shammah users, while women had higher rates of hypertension, diabetes, and dyslipidemia, highlighting the need for gender-specific prevention strategies.

Table 5.2: Frequency of CVD Risk Factors among Cases

Risk Factor	Male				Female				Total
	Yes	%	NO	%	Yes	%	No	%	Yes %
DM	114	30%	262	70%	24	34%	46	66%	31% (138)
Hypertension	150	40%	226	60%	32	46%	38	54%	41% (182)
Smoking	242	65%	131	35%	31	44%	39	56%	61% (273)
Khat chawing	304	81%	72	19%	35	50%	35	50%	76% (339)
Shammah users	64	17%	312	83%	3	4%	67	96%	15% (67)
Dyslipidemia	16	4%	360	96%	6	9%	64	91%	4.9% (22)
Daily smoker	154	41%	222	59%	16	23%	54	77%	38% (170)

5.4: Baseline Demographic and Clinical Characteristics (Table 5.3)

As shown in Table 5.3, presents data on 446 CCU patients at the Military Cardiac Center in Sana'a (2019), categorized into three age groups: ≤50 years (41%), 51–70 years (50%), and >70 years (9%), highlighting the predominance of middle-aged patients.

Age and Sex Distribution The mean patient age was 53.6 ± 13.6 years ($p < 0.001$), with most patients in the 51–70 age group. Female representation rose with age—13% in ≤50 years, 17% in 51–70 years, and 24% in >70 years. While the overall sex distribution was not statistically significant ($p = 0.164$), the age-related increase in female proportion was notable

Cardiovascular Risk Factors by Age Diabetes and hypertension increased significantly with age ($p < 0.001$ and $p = 0.002$), while smoking and khat use were more common among younger patients ($p < 0.01$). For instance, khat use was 82.5% in those ≤50 years versus 59.5% in those >70, reflecting generational behavioral differences.

Clinical History and Comorbidities: Older patients had higher rates of diabetes, hypertension, dyslipidemia, shammah use, and past cardiac interventions (MI, PCI, CABG) ($p < 0.05$). In contrast, smoking and khat use were more common in younger individuals. Rheumatic heart disease (RHD) was more prevalent in younger patients, likely due to early-life exposures. A family history of CAD was notably reported in the middle-aged group, aligning with regional trends in the Gulf States **(5)**.

Table 5.3 – Baseline Demographic and Clinical Characteristics

Variables	<=50 years	51-70 years	>70 years	All group	p.value
Number%	183 (41%)	221 (50%)	42 (9%)	446 (100%)	**0.000**
Sex(female)	13%	17%	24%	16.0%	0.164
Mean Age ± SD	41.1 ± 9.0	59.4 ± 5.1	77.6 ± 6.5	53.6 ± 13.6	**0.000**
DM	21.9%	34.1%	54.8%	31.0%	**0.000**
smoking in a lifetime	69.4%	59.1%	45.0%	62.0%	**0.006**
Daily smoker	44.3%	38.2%	11.9%	38.2%	**0.000**
Former smoker	19%	35%	45%	29%	**0.000**
Khat	82.5%	73.6%	59.5%	76.0%	**0.004**
HTN	31.7%	45.5%	57.0%	40.9%	**0.002**
Shamah user	13.7%	15.0%	21.4%	15.1%	0.448
Dyslipidemia	3.8%	5.9%	4.8%	4.9%	0.631
Family history of CAD	20.0%	29.5%	19.0%	24.5%	**0.050**
Known of CAD	37.7%	40.0%	47.6%	39.8%	0.496
Prior MI	16.4%	25.0%	33.3%	22.2%	**0.023**
Prior PCI	6.6%	12.3%	19.0%	10.6%	**0.030**
History of DM	16.9%	14.1%	7.1%	14.6%	0.258
History of HTN	22.4%	13.6%	9.5%	16.9%	**0,026**
History of khat	3.3%	5.9%	33.0%	7.4%	**0.000**
History of HF	15.8%	18.2%	23.8%	17.8%	0.465
History CABAG	0.5%	4.5%	2.4%	2.7%	**0.047**
history of Cardiac arrest	3%	3%	5%	3%	0.759
History of chest infection	17.5%	12.7%	19.0%	15.3%	0.325
History of DCMP	20%	18%	17%	18%	0.834
History Cardiogenic Shock	19%	11%	10%	14.%	0.078
History Sepsis	2.7%	2.3%	2.4%	2.5%	0.957
History RHD	22.4%	6.8%	4.8%	13.0%	**0.000**

5.5 Clinical and Laboratory Characteristics by Age Group (Table 5.4)

As shown in Table 5.4 the distribution of clinical signs, laboratory findings, and presenting symptoms varied significantly across age groups, revealing several important trends.

Blood Pressure and Blood Sugar Trends- Patients over 70 years of age had the highest systolic blood pressure (SBP), diastolic blood pressure (DBP), and CK-MB enzyme levels, with SBP differences reaching statistical significance ($p = 0.005$). In contrast, younger

patients (≤50 years) had higher levels of total CK and heart rate (HR), though these differences were not statistically significant. The rate of positive cardiac enzyme findings was notably higher among younger patients (72%) compared to older groups (p = 0.024),

Glycemic and Lipid Profiles Random blood sugar (RBS) levels increased significantly with age, with patients >70 years showing the highest mean values (p = 0.006). Fasting blood sugar (FBS), HbA1c, total cholesterol (TC), low-density lipoprotein (LDL), and high-density lipoprotein (HDL) levels were also higher in older age groups, although most differences did not reach statistical significance. These findings suggest that older patients were more likely to present with metabolic comorbidities such as diabetes and dyslipidemia.

Chest Pain Presentation and Dyspnea. Typical chest pain was significantly more common among younger patients (47.5% in ≤50 years vs. 33.3% in >70 years; $p = 0.042$), indicating more classic presentations in younger adults. In contrast, atypical chest pain was more frequent in the older population (38.1% in >70 years; $p = 0.045$), possibly due to age-related physiological changes or comorbidities. Dyspnea (shortness of breath) was reported more frequently with increasing age, affecting 59.5% of patients over 70 compared to 44.3% of those ≤50 years, though the trend was not statistically significant ($p = 0.101$).

Acute Coronary Syndrome Classification ST-Elevation Myocardial Infarction (STEMI) was the most frequent presentation among younger patients, observed in 40.4% of those ≤50 years, but declined to 16.7% in patients >70 years ($p = 0.002$). Conversely, the proportion of patients presenting with Unstable Angina increased significantly with age (from 7.1% in ≤50 years to 23.8% in >70 years; $p = 0.003$). Non-ST-Elevation MI (NSTEMI) also showed a trend toward higher prevalence in older patients, though without significant statistical difference ($p = 0.118$). Khat chewing was associated with higher rates of myocardial infarction (35.4% in khat users vs. 6.5% in non-users) and heart failure

Table 5.6: Baseline demographic and clinical characteristics

Variables	<=50 years	51-70 years	>70 years	All group	p.value
DBP (mmHg) (mean SD)	68 ± 16	69 ± 14	70 ± 17.6	69.1 ± 15	0.925
SBP (mmHg) (mean SD)	111 ± 22	113 ± 25	125 ± 29	113 ± 25	**0.005**
Positive cardiac enzyme	72%	67%	50%	68%	**0.024**
HR (BPM) (mean SD)	92 ± 18	88 ± 20	85 ± 26	89 ± 20	0.071
CK (mean ± SD)	530 ± 780	440 ± 618	391 ± 580	473 ± 688	0.349
CKMP (mean ± SD)	78 ± 107	70 ± 82	87 ± 139	75 ± 99	0.517
FBS mmol/l (mean ± SD)	138 ± 72	142 ± 72	146 ± 58	140 ± 71	0.181
RBS mmol/l (mean ± SD)	142 ± 71	167 ± 106	180 ± 80	158 ± 92	**0.006**
HBA1C	7.7 ± 3	8.0 ± 2.7	8.2 ± 2.7	8.1 ± 2.8	0.810
TC mg/dl/l (mean ± SD)	148 ± 41	144 ± 42	149 ± 44	146 ± 42	0.555
TG mg/dl (mean ± SD)	169 ± 100	160 ± 84	143 ± 74	162 ± 90	0.332
LDL mg/dl (mean ± SD)	90.8 ± 34	85.6 ± 34	93 ± 31	88.3 ± 34	0.293
HDL mg/dl (mean ± SD)	33 ± 8.8	36.3 ± 27	35.8 ± 18	35.0 ± 21	0.407
Chest pain	62% (114)	69.% (153)	57.% (24)	65.% (291)	0.188
Typical chest pain	47.5% (87)	46.2%(102)	33.3% (14)	45.5% (203)	**0.042**
Atypical chest pain	20.8% (38)	27.7% (61)	38.1%(16)	25.8%(115)	**0.045**
Dyspnea	44.3% (81)	52.5%(116)	59.5%(25)	49.8%(222)	0.101
ST-elevation MI	40.4% (74)	28.2% (62)	16.7% (7)	52.6%(143)	**0.002**
NST-elevation MI	9.3% (17)	15.9% (36)	16.7% (7)	22% (60)	0.118
Unstable	7.1% (13)	18.6% (41)	23.8%(10)	23.5% (64)	**0.003**
stable angina	1.6% (3)	0.9% (2)	0.0% (0)	1.8% (5)	0.606

5.6 Medical Therapy and Outcomes (Table 5.5)

As shown in Table 5.5, Medical therapy varied by age. Patients >70 years received more beta-blockers (62%), clopidogrel (76%), statins (74%), ACE inhibitors (55%), and antibiotics (88%) ($p < 0.05$), indicating more intensive care. Younger patients (≤50 years) were more likely to receive pantoprazole (41%), metoprolol (12%), and digoxin (7%). Common therapies overall included aspirin (90%), clopidogrel (74%), statins (63%), antibiotics (70%), ACE inhibitors (35%), and diuretics (43%). Use of dopamine, thrombolytics, and GP IIb/IIIa inhibitors was limited. These trends suggest age-specific pharmacologic management tailored to cardiovascular risk and clinical status.

Table 5.5 Medical therapy

Variables	<=50 years	51-70 years	>70 years	All group	p.value
Aspirin	89%	91%	93%	90.00%	0.528
Beta Blocker	43.0%	54.0%	62.0%	50.0%	**0.018**
Cloipdogrel	67%	79.0%	76.0%	74.0%	**0.030**
GP IIbIIIa inhib	11%	10%	14%	11%	0.763
Heparin	52%	55%	52%	54%	0.794
Diuretic	40%	44%	50%	43%	0.480
Pantoprazole	42%	41%	36%	41%	0.751
Statin	56%	66%	74%	63%	**0.029**
Thrombolytic	8%	4%	10%	6%	0.128
Antibiotics	63%	73%	88%	70%	**0.006**
ACE inhibitor	23%	41%	55.%	35.0%	**0.000**
Morphin	22%	24%	19.%	23%	0.720
Metaprolal	14%	10%	10%	12.%	0.445
Assits	9%	9%	19%	10%	0.108
Angised	8%	9%	12%	9%	0.742
Pantocid	29%	36%	48%	34%	0.054
Digoxin	8%	6%	2%	7%	0.456
Dopamine	8%	9%	5%	8%	0.694
Aldactone	15%	15%	19%	15%	0.786
Duphlac	8%	9%	17%	9%	0.211

5.7 Clinical Outcomes (Table 5.6)

As shown in Table 5.6, Complications occurred in 40.8% of patients, with nosocomial infections (25%, p = 0.008), septicemia (7%, p = 0.000), and chest infections (7%) being the most common. Other complications included mural thrombus (4%), bleeding, emergency surgery, renal impairment, and conduction block (1–3%). Khat chewers had significantly more complications (31.1%) than non-chewers (9.4%), consistent with reports linking khat to increased stroke and mortality risk **(7).**In-hospital mortality was higher in patients >70 years (17%) compared to ≤50 years (13%). Five-year mortality also followed this trend (21% vs. 20%), in line with regional findings **(5).**

Table 5.6: Outcome and Mortality

Variables	<=50 years	51-70 years	>70 years	All group	p.value
Infection	32%	22%	12%	25%	**0.008**
Cardiac valve injury	2%	0%	0%	1%	0.368
L V thrombus	3%	3%	0%	3%	0.499
Mural thrombus	6%	4%	0%	4%	0.218
Blood transfusion	3%	2%	2%	3%	0.815
Urgent cardiac surgery	4%	3%	2%	3%	0.874
Renal Impermeant	1%	2%	5%	2%	0.136
Chest infection	6%	8%	2%	7%	0.416
Sepsis	7%	5%	14%	7%	0.**000**
P. Oedema	0%	1%	2%	1%	0.200
Conduction block	2%	1%	0%	2%	0.555
Cardiac arrest	4%	5%	7%	4%	0.646
Diarrhea	1%	1%	0%	1%	0.777
Warfarin Toxicity	1%	1%	2%	1%	0.103
In hospital mortality	13%	15%	17%	14%	0.791
Mortality during 5 years	20%	18%	21%	19%	0.809

5.8 Distribution of Overall Outcomes by Final Diagnosis (Table 5.7)

As shown in Table 5.7 The overall in-hospital mortality rate was 14.3% (64/446). Acute coronary syndrome (ACS) was the primary cause, accounting for 26 deaths (5.8%, p = 0.000), with STEMI contributing 19 (4.3%) and NSTEMI 5 (1.1%). Unstable angina was significantly associated with mortality (p = 0.001). Acute decompensated heart failure (ADHF) caused 15 deaths (3.4%, p = 0.008), and cardiogenic shock 7 (1.6%, p = 0.033). Valve heart disease accounted for another 7 deaths (1.6%). Less common fatal diagnoses included dilated cardiomyopathy (DCMP), pulmonary hypertension (P.HTN, p = 0.020), hypertensive emergencies, and pericarditis. These data emphasize the strong link between ischemic and decompensated cardiac conditions and mortality in this population.

Table 5.7: Distribution of the overall outcome of the patients by their diagnosis (n= 446)

Final diagnosis	Alive	%	Dead	%	TOTAL	P.value
ACS	246	55.1%	26	5.8%	272	**0.000**
ACS (STEMI)	124	27.8%	19	4.3%	143	0.388
ACS (NSTEMI)	55	12.3%	5	1.1%	60	0.105
ACS (Unstable)	62	13.9%	2	0.4%	64	**0.001**
ACS SA	5	1.1%	0	0.0%	5	0.105
ADHF	42	9.4%	15	3.4%	57	**0.008**
Arrhythmia	5	1.1%	0	0.0%	5	0.459
Cardiogenic Shock	16	3.6%	7	1.6%	23	**0.033**
Congenital heart disease	17	3.8	0	0.0$	17	0.068
COPD	4	0.9%	0	0.0%	4	0.537
DCMP	14	3.1%	4	0.9%	18	0.250
Hypertensive Emergency	1	0.2%	1	0.4%	2	0.267
LV THROMBUS	1	0.2%	1	0.2%	2	0.267
P.Embolism	2	0.4%	0	0.0%	2	0.733
P.HTN	0	0.0%	2	0.4%	2	**0.020**
Pericarditis	1	0.2%	1	0.2%	2	0.267
VHD	33	7.4%	7	1.6%	40	0.345
TOTAL	382	5.8%	64	14.3%	446	

5.9 Risk Factors Associated with Cardiovascular Diagnoses (Table 5.8)

As shown in Table 5.8,, acute coronary syndrome (ACS) was significantly associated with delayed smoking (p = 0.000) and diabetes (p = 0.002). STEMI showed associations with smoking (p = 0.004), hypertension (p = 0.012), diabetes (p = 0.015), khat chewing (p = 0.009), and delayed smoking (p = 0.000). NSTEMI was linked to shammah users (p = 0.046), while unstable angina was related to smoking (p = 0.005) and khat (p = 0.014). Heart failure subtypes also showed strong associations: ADHF with smoking (p = 0.017), diabetes (p = 0.000), and hypertension (p = 0.002), while rheumatic heart disease was linked to smoking (p = 0.007), hypertension (p = 0.001), diabetes (p = 0.000), and delayed

smoking (p = 0.009). These findings underscore the impact of modifiable risk factors on cardiovascular outcomes.

Table 5.8: Risk factors associated with CVD patient diagnosis

final Diagnosis	ACS	STEMI	NSTEMI	U.A	ADHF	C, shock	DCMP	RHD
Smoking	174	102	40	30	43	15	11	17
P.value	0.180	**0.004**	0.263	**0.005**	**0.017**	0.469	0.556	**0.007**
HTN	105	47	26	31	34	12	8	7
P.value	0.139	**0.012**	0.385	0.115	**0.002**	0.178	0.469	**0.001**
DM	70	34	138	16	34	7	9	2
P.value	**0.002**	**0.015**	0.502	0.167	**0.000**	0.580	0.067	**0.000**
Khat user	213	119	49	41	43	17	15	30
P.value	0.096	**0.009**	0.174	**0.014**	0.514	0.488	0.337	0.504
Shammah users	45	67	14	24	10	3	3	3
P.value	0.161	0.382	**0.046**	0.515	0.344	0.537	0.524	0.118
Dely smoking	125	76	23	8	16	5	4	8
P.value	**0.000**	**0.000**	0.539	0.347	0.062	0.072	0.119	**0.009**

5.10 Predictors of In-Hospital Mortality – Univariate Binary Logistic Regression (Table 5.9)

As shown in Table 5.9, univariate binary logistic regression identified several variables significantly associated with in-hospital mortality ($p < 0.05$)..

Clinical history: Key predictors included diabetes mellitus (OR 2.6), rheumatic heart disease (OR 2.4), dilated cardiomyopathy (OR 3.6), heart failure (OR 9.2), renal impairment (OR 3.5), chronic lung disease (OR 8.0), oedema (OR 3.2), and former smoking (OR 2.1).

Presentation features: Strong predictors included cardiogenic shock (OR 11.3), cardiac arrest (OR 5.5), dyspnea (OR 6.9), positive cardiac enzymes (OR 3.9), and elevated CK-MB (OR 3.3).

Diagnostic categories: Mortality was associated with acute coronary syndrome (OR 2.6), cardiogenic shock (OR 2.8), and acute decompensated heart failure (OR 2.5), while unstable angina was protective (OR 0.2).

In-hospital complications: The strongest predictors were complications of cardiac arrest (OR 74), sepsis (OR 31.1), pulmonary oedema (OR 18.7), shocked liver (OR 9.7), and infection (OR 2.5).

These findings emphasize the importance of early recognition and management of high-risk factors to improve hospital outcomes.

Table 5.9: Univariate Binary Logistic Regression Analysis for In-Hospital Mortality

Variable	In hospital mortality		
	OR	**95% C. L**	**p.value**
Gender	1.6	0.3 – 3.7	0.260
Age	1.4	0.4 – 4.6	0.450
Hypertension	1.6	0.9 – 2.6	0.108
Khat	1.4	0.8 – 2.5	0.250
D.M	2.6	1.5 - 4.5	**0.000**
Smoking	1.19	0.7 – 2.1	0.531
History of CAD	1.0	0.5 – 1.9	0.910
History of RHD	2.4	1.2 – 4.7	**0.009**
History of Cardiogenic Shock	11.3	6.1 – 20.9	**0.000**
History of Cardiac Arrest	5.5	1.8 – 17	**0.003**
History of DCMP	3.6	2.0 – 6.5	**0.000**
F.History of DM	1.6	0.82 -3.2	0.163
History of a former smoker	2.1	1.2 – 3.6	**0.007**
History of Heart failure	9.2	5.1 – 16.6	**0.000**
History of Renal Impairment	3.5	1.5 – 8.3	**0.004**
History of post-SK	4.5	1.2 – 16.4	**0.023**
History of Chronic Lung Disease	8.0	2.1 – 30.6	**0.002**
History of Oedema	3.2	1.5 – 6.36	**0.001**
History of P.Effusion	10.7	2.4 – 45.9	**0.001**
Presentation of Sepsis	31.1	6.5 - 147	**0.000**
Presentation of Chest Infection	2.6	1.4 – 4.8	**0.003**
Presentation of Septic Shock	8.0	2.1 – 30.7	**0.002**
Presentations CPR in ER	4.1	1.5 – 10.9	**0.005**
CCU CPR	1.1	0.1 – 3.0	0.899
Presentation of Shocked liver	13.2	1.1 - 148	**0.036**
Presentation of Dyspnea	6.9	3.4 – 13.9	**0.000**

Presentation of Dyspnea Class II	3.5	1.8 – 6.9	**0.000**
Presentation of Dyspnea Class III	2.7	1.4 – 5.1	**0.002**
Presentation of Dyspnea Class IV	2.2	1.1 – 4.5	**0.022**
Positive Cardiac enzyme	3.9	1.8 – 8.4	**0.001**
CKMP	3.3	1.4 – 7.8	**0.004**
Aldactone	2.1	1.1 - 3.9	**0.025**
Duphlac	3.6	1.8 – 7.5	**0.000**
ACS	2.6	1.5 – 4.5	**0.000**
ACS (STEMI)	0.9	0.4 – 1.6	0.660
ACS (NSTEMI)	0.5	0.19 – 1.3	0.160
ACS US	0.2	0.4 – 0.7	0.014
VHD	1.3	0.5 – 3.0	0.552
ADHF	2.5	1.3 – 4.8	**0.007**
Cardiogenic shock	2.8	1.1 – 7.1	**0.030**
DCMP	1.8	0.6 – 5.5	0.337
Chest pain	1.9	1.1 – 3.3	**0.014**
Typical chest pain	1.5	0.9 – 2.7	0.098
Atypical chest pain	2.3	1.1 – 4.9	**0.024**
Age group	1.3	0.5 – 3.3	0.548
51-70 years	1.1	0.6 – 1.8	0.728
>70 years	1.2	0.5 – 2.8	0.653
Complication of Infection	2.5	1.5 – 4.5	**0.001**
Complications of Cardiac arrest	74	16.7 - 330	**0.000**
Complication of P.odema	18.7	1.9 - 183	**0.012**
Complication of Shocked liver	9.7	2.8 – 35.7	**0.001**
Complication of Sepsis	5.8	2.7 – 12.6	**0.000**
Complications of Cardiac Valve Injury	18.7	1.9 – 183	**0.012**

5.11: Predictors of In-Hospital and 5-Year Mortality (Table 5.10)

As shown in Table 5.10, univariate binary logistic regression identified several variables significantly associated with both in-hospital and 5-year mortality. Key findings include:

Pharmacologic and procedural interventions, Clopidogrel (OR 2.5), beta-blockers (OR 2.3 and 2.1), and statins (OR 1.8 and 2.4) were significantly associated with increased mortality. Elective PCI (OR 2.6 and 2.9) and left heart catheterization (OR 4.9 and 3.5) predicted mortality in both periods.

Symptoms and clinical presentation: Chest pain (OR 1.9 and 2.6) and atypical chest pain (OR 2.3 and 2.0) predicted higher mortality. Unstable angina was protective during hospitalization (OR 0.2) but linked to higher long-term risk (OR 8.7).

Diagnosis and outcomes: ACS increased mortality in both periods (OR 2.6 and 4.0). Cardiac arrest complications were the strongest in-hospital predictor (OR 74) .

Procedural outcomes: Even though PPCI was not statistically linked to a lower death risk (OR 0.88 and 1.2), its early use might still help patients and lead to better recovery.

These results show that different factors affect short-term and long-term mortality, and emphasize the need for personalized treatment strategies at each stage of care.

Table 5.10: Univariate Binary Logistic Regression for In-Hospital and within 5-Year Mortality

Variable	In hospital mortality			Mortality within 5 years		
	OR	**95% C. L**	**p.value**	**OR**	**95% C. L**	**p.value**
Khat	0.71	0.4 – 1.2	0.009	**2.0**	1.1 – 3.2	**0.009**
Clopidogrel	**2.5**	1.5 – 4.0	**0.001**	**2.5**	1.5 – 4.0	**0.001**
Beta-blocker	**2.3**	1.3 - 4.1	**0.003**	**2.1**	1.3 – 3.6	**0.002**
Metoprolol	3.0	0.9 - 10	0.067	**3.2**	1.1 – 9.2	**0.029**
Statin	**1.8**	1.0 - 3.1	**0.026**	**2.4**	1.5 – 3.9	**0.000**
Elective PCI	**2.6**	1,1 – 5.9	**0.021**	**2.9**	1.0 – 8.3	**0.004**
Lt Catheterization	**4.9**	2.6 - 9.2	**0.000**	**3.5**	2.1 – 5.7	**0.000**
PPCI	0.88	0.2 – 2.9	0.77	1.2	0.3 – 4.2	0.775
ACS	**2.6**	1.5 – 4.5	**0.000**	**4.0**	2.4 – 6.6	**0.000**
ACS US	**0.2**	0.4 – 0.7	**0.014**	**8.7**	2.3 – 36	**0.002**
Chest pain	**1.9**	1.1 – 3.3	**0.014**	**2.6**	1.6 1 4.2	**0.000**
Typical chest pain	1.5	0.9 – 2.7	0.098	**2.3**	1.4 – 4.0	**0.001**
Atypical chest pain	**2.3**	1.1 – 4.9	**0.024**	**2.0**	1.0 -3.7	**0.027**
Complications of cardiac arrest	**74**	16.7 - 330	**0.000**	0.01	0.01 – 0.7	0.000

6.0 Discussion:

6.1. Age Group Distribution

The current study showed that only 7% of patients were aged 18–30 years, a figure higher than reports from Germany (1.7%) and New York (1.8%) but close to Bangladesh (9%)***(8-10).*** This may reflect early exposure to modifiable risk factors like khat chewing, smoking, and a sedentary lifestyle.

The most affected group was aged 51–60 years (34%), which contrasts with findings in Europe, where older patients predominate. For example, 30.3% of patients in the Netherlands were over 75, and 55.5% in Denmark were over 70 ***(11, 12).*** In Yemen, only 9% were over 70.

Notably, 41% of Yemeni patients were under 50, compared to only 9% in Denmark and 8% in the Netherlands. This suggests early onset of cardiovascular disease in Yemen, likely due to poor access to preventive care and social determinants such as poverty and stress. These disparities underscore the need for youth-focused cardiovascular screening and public health interventions in low-resource settings.

6.2. Distribution of Cases by Final Diagnosis and Sex

STEMI was more common in males, whereas RHD and congenital heart disease were more prevalent in females, aligning with global patterns. Male dominance (84%) in this study was notably higher than in Egypt (74%), Saudi Arabia (72.3%), and North America (50–63%) ***(13-15)*** This skewed ratio may be due to the military hospital setting and barriers limiting female access to care. The findings highlight the need for gender-sensitive policies that promote earlier diagnosis and equitable treatment for women.

6.3 Cardiovascular Risk Factors in the Yemeni Population

Obesity remains relatively low in Yemen, with a prevalence of 8.8%, compared to much higher rates in Saudi Arabia (39.6%) and Egypt (46% in females). Cultural practices, food availability, and levels of physical activity likely explain this difference. Western countries, where obesity rates between men and women are more equal, benefit from shared societal

roles and improved health awareness. In this study, diabetes was found in 31% of patients—lower than in Gulf countries (57–63%) and Egypt (43%) but higher than in Europe and Latin America (11–25%). Yemen's lower rate may reflect a continued reliance on traditional diets and limited processed food consumption. Hypertension was present in 41% of cases, which is lower than in the Gulf (e.g., 65% in Saudi Arabia and 60.9% in the UAE) but close to rates in North Africa (45%). In contrast, Europe has much lower rates (15.7–19.2%), possibly due to more effective prevention and early intervention.

Smoking was reported in 61% of patients, much higher than in the Gulf (34%), Egypt (48.1%), and North Africa (14%) **(16, 17)**. Smoking was particularly prevalent among khat users (69.6%), and only 2% of patients were neither smokers nor khat chewers. This highlights a compounding effect of cultural habits on risk exposure, emphasizing the need for locally tailored prevention strategies.

Hypertension was found in 41% of patients, lower than in Gulf countries like Saudi Arabia (65%) and the UAE (60.9%), but similar to North Africa (45%). The higher rates in the Gulf may be linked to obesity, fast food, and low activity, while khat chewing may influence rates in Yemen. In Europe, lower prevalence (15.7%–19.2%) reflects healthier lifestyles and better preventive care.

In this study, 61% of patients were smokers, much higher than in the Gulf (34%) (**16**), Egypt (48.1%) (**13)**, and North Africa (14%) **(17).** Smoking was especially common among khat users (69.6%), while only 2% of patients were neither smokers nor khat chewers. Khat chewing appears to increase both cigarette use and passive smoking exposure in enclosed spaces. These findings underscore the urgent need for context-specific cardiovascular prevention strategies, improved emergency response systems, and equitable access to early diagnostic and interventional cardiology services in Yemen.

6.4 Refined Discussion – Clinical Characteristics and Risk Profiles (Table 5.6)

Mean fasting blood glucose was 140 ± 71 mg/dL, random glucose 158 ± 92 mg/dL, systolic pressure 113 ± 25 mmHg, and diastolic 69.1 ± 15 mmHg—values lower than those reported in Saudi Arabia and the UAE **(18, 19)** potentially due to Yemen's limited access to care

and dependence on home-cooked food. Heart rate was higher (89 ± 20 bpm) than in the Gulf (84.6 bpm) and Europe (France 82.5 bpm, Portugal 59.7–65 bpm) **(5, 20, 21)** possibly due to widespread khat chewing and sympathetic stimulation. Lipid profiles were generally lower: total cholesterol 3.78 mmol/L, LDL 2.28 mmol/L, HDL 0.9 mmol/L, and triglycerides 1.8 mmol/L—well below levels in Saudi Arabia and Egypt **(22, 23)**, Still, only 4.9% had diagnosed dyslipidemia, compared to 82.7% in Saudi Arabia and 57% in Gulf countries (**16, 24)**, suggesting underdiagnosis. Typical chest pain was present in 69.7% of cases, with dyspnea frequent in patients ≥70 years. STEMI was the most common presentation (52.3%), surpassing Canada (40.7%) and Europe (42.5%) **(24, 25)**likely reflecting delayed care and a younger affected population.

ACS subtypes varied with age: STEMI declined from **40.4%** (≤50 years) to **16.7%** (>70 years), while NSTEMI and unstable angina increased with age ($p < 0.005$). This pattern aligns with global data showing atypical presentation in the elderly.

Past cardiac history was less common than in neighboring countries: CAD (24.5%), MI (22.2%), PCI (10.6%), CABG (2.7%)—versus higher rates in Saudi Arabia and Portugal **(21, 26).**

In conclusion, the Yemeni ACS profile reflects a mix of region-specific risks (khat, smoking), socioeconomic constraints, and delays in care. These insights stress the need for preventive strategies and improved cardiac healthcare systems in Yemen.

6.5 Medical Therapy and Outcomes (Table 5.7)

Therapeutic interventions differed significantly by age. Patients >70 received more aspirin (93%), beta-blockers, ACE inhibitors, antibiotics, statins, and diuretics ($p < 0.05$). Clopidogrel and morphine were more common in the 51–70 age group, while metoprolol and digoxin were used more in younger patients. Only 18.1% of STEMI patients received thrombolysis, and 12.6% qualified for PPCI, reflecting significant gaps in reperfusion therapy.

Complications occurred in 42.8% of cases (n=191), with infections being most frequent (25%, $p = 0.008$), including sepsis and chest infections (7%, $p = 0.000$). Bleeding, renal

failure, and conduction block affected 2–3% of patients. In-hospital mortality was 14.3%, while five-year mortality was 19.3%, considerably higher than in Saudi Arabia (7.9%) and Portugal (3.9%) **(21, 26).** These outcomes likely stem from late presentation and inadequate infection control.

In contrast to the Netherlands, where 60% of cardiac patients access rehabilitation (reducing recurrence by 31% **(27) ,** Yemen lacks structured programs and public health insurance, especially in government hospitals. This highlights the urgent need for improved emergency care, continuity of care, and a digital risk stratification system in facilities like the Military Cardiac Center in Sana'a.

7.1 Conclusion

This study revealed a critical gap in the management of STEMI patients in Yemen, with only 30.1% receiving any form of reperfusion therapy—12.6% via PCI and 18.1% via streptokinase. The majority (69.9%) did not receive reperfusion, likely contributing to the high in-hospital mortality rate of 14.3%, which surpasses regional benchmarks. These findings underscore severe systemic limitations, including inadequate access to interventional cardiology, delayed patient presentation, lack of emergency medical services, and the absence of universal health coverage. Addressing these gaps is essential to improve outcomes for acute cardiac patients in Yemen.

7.2 Recommendations

Based on the study findings, the following actions are recommended to address the burden of ACS in Yemen:

1. Launch public awareness campaigns targeting modifiable cardiovascular risk factors.
2. Introduce universal health insurance to improve equitable access to care.
3. Develop emergency medical transport systems for timely hospital access.
4. Offer free annual cardiac screenings for individuals aged >30, particularly in rural areas.

5. Guarantee free treatment for ACS in public hospitals.
6. Expand cardiac care services by establishing specialized centers nationwide.
7. Implement electronic health records and risk stratification tools for ongoing patient monitoring.

8.0 References

1. Organization WH. Cardiovascular diseases (CVDs) 2019 [11 July 2025]. Available from: https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds).
2. Al-Motarreb A, Broadley KJ. Khat: pharmacological and medical aspects and its social use in Yemen. Phytother Res. 2002;16(5):403-13.
3. Jagannathan, R, Patel, S A, Ali, M K, et al. Global updates on cardiovascular disease mortality trends and attribution of traditional risk factors. Current diabetes reports. 2019;19:1-12.
4. Saleh THA. A review of burden and determinants of cardiovascular diseases and diabetes among the adult population in Yemen. 2020.
5. Ahmed, E, Alhabib, K F, El M, A, et al. Age and clinical outcomes in patients presenting with acute coronary syndromes. Journal of cardiovascular disease research. 2013;4:134-9.
6. Al-Ghamdi MA. Morbidity pattern and outcome of patients admitted in a coronary care unit: a report from a secondary hospital in southern region, Saudi Arabia. Journal of Community Hospital Internal Medicine Perspectives. 2018;8(4):191-4.
7. Ali WM, Zubaid M, Al-Motarreb A, Singh R, Al-Shereiqi SZ, Shehab A, et al., editors. Association of khat chewing with increased risk of stroke and death in patients presenting with acute coronary syndrome. Mayo Clinic Proceedings; 2010: Elsevier.
8. Chowdhury, A W, Alam, N, Khan, H. L R, et al. The pattern of cardiac disease at coronary care unit of Dhaka Medical College Hospital. Cardiovascular Journal. 2015;7:119-22.
9. Heigl F, Hettich R, Lotz N, Reeg H, Pflederer T, Osterkorn D, et al. Efficacy, safety, and tolerability of long-term lipoprotein apheresis in patients with LDL-or Lp (a) hyperlipoproteinemia: Findings gathered from more than 36,000 treatments at one center in Germany. Atherosclerosis Supplements. 2015;18:154-62.
10. Lala, A, Johnson, K W, Januzzi, J L, et al. Prevalence and impact of myocardial injury in patients hospitalized with COVID-19 infection. Journal of the American college of cardiology. 2020;76:533-46.
11. Eijsvogels TM, Maessen MF, Bakker EA, Meindersma EP, van Gorp N, Pijnenburg N, et al. Association of cardiac rehabilitation with all-cause mortality among patients with cardiovascular disease in the Netherlands. JAMA Network Open. 2020;3(7):e2011686-e.
12. Özcan C, Deleskog A, Schjerning Olsen A-M, Nordahl Christensen H, Lock Hansen M, Hilmar Gislason G. Coronary artery disease severity and long-term cardiovascular risk in patients with myocardial infarction: a Danish nationwide register-based cohort study. European Heart Journal–Cardiovascular Pharmacotherapy. 2018;4:25–35.
13. Reda A, Bendary A, Elbahry A, Farag E, Mostafa T, Khamis H, et al. Prevalence of atherosclerosis risk factors in Egyptian patients with acute coronary syndrome: final data of the nationwide cross-sectional 'CardioRisk' project. Journal of Public Health in Africa. 2020;11.

14. Laverty C, Green KD, Dick JT, Barrios-O'Neill D, Mensink PJ, Médoc V, et al. Assessing the ecological impacts of invasive species based on their functional responses and abundances. Biological Invasions. 2017;19:1653-65.
15. Bohula, E A, Katz, J N, Van D, S, et al. Demographics, care patterns, and outcomes of patients admitted to cardiac intensive care units: the Critical Care Cardiology Trials Network Prospective North American Multicenter Registry of Cardiac Critical Illness. JAMA cardiology. 2019;4:928-35.
16. Al-Zakwani I, Al-Lawati J, Alsheikh-Ali AA, Almahmeed W, Rashed W, Al-Mulla A, et al. Impact of Dual versus Single Antiplatelet Therapy on Major Cardiovascular Outcomes in Patients with Acute Coronary Syndrome in the Arabian Gulf. 2020;29:181–7.
17. Nejjari C, Arharbi M, Chentir M-T, Boujnah R, Kemmou O, Megdiche H, et al. Epidemiological Trial of Hypertension in North Africa (ETHNA): an international multicentre study in Algeria, Morocco and Tunisia. Journal of Hypertension. 2013;31:49–62.
18. Gazzaz ZJ, Iftikhar R, Jameel T, Baig M, Murad MA. Association of dyslipidemia and comorbidities with risk factors among diabetic patients: a retrospective analysis. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. 2020:935–41.
19. OSMAN W, HASSOUN A, JELINEK HF, ALMAHMEED W, AFANDI B, TAY GK, et al. Genetics of type 2 diabetes and coronary artery disease and their associations with twelve cardiometabolic traits in the United Arab Emirates population. Gene. 2020;750:144722.
20. YAYEHD K, N'KENON W, BELLE L, BATAILLE V, HANSSEN M, LEDDET P, et al. Management of Takotsubo cardiomyopathy in non-academic hospitals in France: The Observational French SyndromEs of TakoTsubo (OFSETT) study. Archives of cardiovascular diseases. 2016;109:4-12.
21. AGUIAR ROSA S, TIMóTEO AT, FERREIRA L, CARVALHO R, OLIVEIRA M, CUNHA P, et al. Complete atrioventricular block in acute coronary syndrome: prevalence, characterisation and implication on outcome. European Heart Journal: Acute Cardiovascular Care. 2018;7:218-23.
22. MOHSEN MM, RIAD NA, BADAWY AI, ABD EL-HAMMED BM, ELSHERBINI DMAE. Effectiveness of Life Style Modification on Lipid Profile for Patients with Hyperlipidemia. American Journal of Nursing. 2020;9:8-18.
23. ALQUAIZ AM, KAZI A, YOUSSEF RM, ALSHEHRI N, ALDURAYWISH SA. Association between standardized vitamin 25 (OH) D and dyslipidemia: a community-based study in Riyadh, Saudi Arabia. Environmental health and preventive medicine. 2020;25:1-9.
24. KAUL P. Acute Coronary Syndromes in Canada: Contemporary Management and Outcomes. Canadian Journal of Cardiology. 2019;35:141-3.
25. ROSENGREN A, WALLENTIN L, KORHONEN M, GITT AK, BRIEGER D, ALEXANDER KP, et al. Cardiovascular risk factors and clinical presentation in patients with acute coronary syndromes: a global perspective from the Euro Heart Survey of Acute Coronary Syndromes. European Heart Journal. 2006;27:2394–402.
26. STEG PG, GOLDBERG RJ, GORE JM, FOX KAA. Baseline characteristics, management practices, and in-hospital outcomes of patients hospitalized with acute coronary syndromes in the Global Registry of Acute Coronary Events (GRACE). American Journal of Cardiology. 2002;90:358-63.
27. EIJSVOGELS TMH, GEUZEBROEK GSC, MAASSEN MFH, DE MUNTER JSL, THIJSSEN DHJ, HOPMAN MTE. The impact of cardiac rehabilitation on mortality risk reduction after acute coronary syndrome: A Dutch nationwide cohort study. European Journal of Preventive Cardiology. 2020;27:2294–302.

Appendix A: Declaration of English reviewer approval

Republic of Yemen
Ministry of Education & Scientific Research
Al-Razi University

R U

الجمهورية اليمنية
وزارة التربية والتعليم والبحث العلمي
جامعة الرازي

Approval (Declaration of Language Reviewer)

This is to certify that this study entitled:

(*Clinical Presentation, Risk Factor, Course and Outcome of the CVD in the Military Cardiac Center, Sana'a, Yemen*),

submitted by: (*ABDULELAH MANSOOR MOHAMMED AL-GANAD*), who is registered in the Department of Community Health and Nutrition, Faculty of Medicine and Health Sciences, Al-Razi University, has been linguistically reviewed, edited and proofread.

Therefore, this study is ready for final viva examination and publication.

Dr. Sharaf Shana
Language Reviewer
Head of Translation Unit - Al-Razi University

صنعاء - شارع الرباط - خلف البنك اليمني للإنشاء والتعمير
406760 774440012 216923

حجة - شارع الحديدة - جوار بنك التضامن وبنك اليمن والكويت
06760 774440015 07220708

www.alraziuni.edu.ye alraziuni.edu.ye RaziUni info@alraziuni.edu.ye

Appendix D: Scientific Review Confirmation



Republic of Yemen
Ministry of Education & Scientific Research
Al-Razi University

الجمهورية اليمنية
وزارة التربية والتعليم والبحث العلمي
جامعة الرازي

Date: [28 /7 /2025]

Scientific Review Confirmation

To Whom It May Concern,

I hereby confirm that I have thoroughly reviewed the research manuscript submitted by the student **Mr. Abdulelah Mansoor Mohammed Al-Ganad**, titled "Clinical Presentation, Risk Factors, and Outcomes of Cardiovascular Disease in a Military Cardiac Center in Yemen". After careful evaluation, I confirm that the research methodology is sound, the statistical analysis is precise, and the clinical findings are appropriate and relevant. Therefore, I affirm that this research is suitable for academic dissemination and publication.

Please do not hesitate to contact me if you require any further information or clarification regarding this review.

Sincerely,

Dr. Nabil A. Al-Rabeei
Professor of Public health and statistics
Faculty of Medicine - Sana'a University
Emile: N.alrabeei@su.edu.ye

صنعاء - شارع الرباط - خلف البنك اليمني للإنشاء والتعمير 406760 774440012 216923
حجة - شارع العديدة - جوار بنك التضامن وبنك اليمن والكويت 406760 774440015 07220708
www.alraziuni.edu.ye alraziuni.edu.ye RaziiUni info@alraziuni.edu.ye

Appendices (Ethical Approvals and Institutional Permissions)

- **Appendix B – Title Consent from Digital Library of the National Information Center**

This document confirms that the research was registered in the national digital repository. The original consent letter (in Arabic) is available upon request from the corresponding author.

- **Appendix C – Military Cardiac Center Approval**

Formal institutional permission was obtained from the Military Cardiac Center in Sana'a, Yemen. The Arabic-language approval letter is available upon request from the corresponding author.

- **Appendix E – Supervisory Letter to Prof. Ahmed Al-Mutarb**

This letter outlines the academic supervision and endorsement of the study. The original letter is written in Arabic and can be provided upon request.

Note: All supporting Arabic documents have been removed from this version of the manuscript to comply with medRxiv's policy. Please contact the corresponding author for access to these materials.

Author Statement

This thesis was submitted by **Abdulelah Mansoor Mohammed Al-Ganad** in full fulfillment of the requirements for the Master's degree in *Epidemiology and Medical Biostatistics* at **Al-Razi University**, Sana'a, Yemen.

Acknowledgements

The authors gratefully acknowledge Dr. Ahmed Al-Motarreb, Dr. Taha Al-Maimoony, and Prof. Nabil Al-Rabeei for their invaluable supervision and review of this research. We also extend our thanks to Al-Razi University and the Military Cardiac Center for their institutional support and to the National Information Center for assisting with data access and record verification.

Author Contributions

Abdulelah Mansoor Al-Ganad: Conceptualized and designed the study, developed the research methodology, collected clinical data, performed statistical analysis, interpreted the results, drafted the initial manuscript, formatted tables and figures, prepared the final version of the paper, and submitted the preprint. He is the corresponding author.

Prof. Ahmed Al-Motarreb: Professor of Cardiology and Head of the Cardiology Department, Faculty of Medicine – Sana'a University. He served as the principal academic supervisor for the entire study, providing continuous guidance throughout all phases of the research. His extensive expertise in cardiology was instrumental in shaping the study design, interpreting clinical data, and ensuring the scientific rigor of the study. He also offered critical feedback and a thorough manuscript review, significantly enhancing the quality and clarity of the final work.

Dr. Taha Al-Maimoony: Associate Professor of Cardiology – Sana'a University, and the external examiner of the master's thesis. He provided valuable scientific comments that were integrated into the final published version.

Prof. Nabil Al-Rabeei: Professor of Public Health and Medical Biostatistics – Al-Razi University; internal supervisor of the master's thesis. He supervised and reviewed the statistical analysis and contributed to improving the methodological quality.

Dr. Abdulaziz Mohammed Ali Aonallah: Assisted in collecting clinical data from patient records at the Military Cardiac Center in Sana'a.

Dr. Esmail Mohamed Sad Al-Dabis: Made a significant contribution to data analysis and quality assurance.